A letter to the Federal Trade Commission (FTC), recently sent from the FAH, addressed two issues of crucial importance when building efficient and competitive markets: price and quality transparency.
Price Transparency
Price transparency is necessary in order for patients to easily determine the cost of their premiums, deductibles, copayments and non-covered services (“Out-of-Pocket Costs”) prior to purchasing health insurance coverage and receiving medical services. Our letter outlines five key principles from the Healthcare Financial Management Association Price Transparency Task Force that the FAH believes are critical to defining price transparency. Under these principles, price transparency should:
- Enable patients to make informed price comparisons and make decisions based off which providers offer them the most value;
- Be easy to use and communicate;
- Be paired with information that defines the value of service for the consumer;
- Provide patients with information needed to understand total price of their care and what is included in that price; and,
- Require commitment and active participation of all stakeholders.
Unfortunately, hospital price transparency can be complicated and is often made worse, as a previous blog outlines, when the different terms used to discuss hospital financing are applied incorrectly. For example, “payments,” “costs,” “charges,” and “prices” are separate terms with entirely separate definitions. Unfortunately, these words are often – and inaccurately – used interchangeably.
The focus placed on hospitals charges has been the root of much confusion. If there is one critical takeaway, it is this: listed charges have little relevancy to most patients, as charges and the amount patients are expected to pay are often much different. Clear definitions and understanding of the difference between cost, charge and payment are vital to developing a transparent pricing structure in health care.
Further, price transparency cannot be the sole responsibility of providers. To ensure that all patients understand the care they receive, all stakeholders must be accountable in clarifying for consumers the breakdown of care provided. For consumers with health insurance, insurers should be the consumer’s point of contact for all information related to insurance coverage and payment for medical services, including Out-of-Pocket Costs, coverage, benefits, providers, insurer ratings and reliability of claims payments. This is especially true when medical services are furnished by multiple providers, which makes understanding the costs of care difficult. Insurers should serve as consumers’ source for “one-stop” shopping.
In the discussion on price transparency there is one important item of note. While the FAH supports price transparency, we do not believe that negotiated provider network payment rates should be disclosed due to anticompetitive concerns. As recognized by economists and the FTC, transparency of provider network rates could inflate prices, incentivizing providers with lower price structures to raise their prices to match higher rates in the same market.
Quality Transparency
Inherent in effective price transparency is the need to pair price data with meaningful quality data through public reporting of performance. Quality transparency will give insight into the value of care a patient receives. As the FAH’s letter to the FTC outlines, there have been significant strides in developing and implementing quality reporting programs over the last decade, but the challenges that remain are equally significant. The FTC should assess these issues as it examines quality measures.
The FAH outlines four principles that it urges the FTC to follow when it comes to examining quality measurement:
- Measurement and reporting should be meaningful and actionable;
- Measure development, reporting and endorsement should be consensus-based and include a broad range of important stakeholders in these processes;
- Measurement and performance reporting should be based on consistency of measurement across providers and settings; and,
- Public reports of provider performance should have purpose, transparency and validity.
In addition to these principles, the FAH urges the FTC to recognize the ongoing limitations in measuring and reporting quality performance that exist at this point in the quality enterprise continuum. There are a number of examples that outline the challenge in trying to measure quality during this developmental phase:
- Effective methods for utilizing interoperable electronic health records (EHRs) have yet to be determined.
- Although we are in the early stages of transitioning from emphasis on process measurement to outcome-based measurement to identify quality health care providers, there are not sufficient outcome-based measures to make broad determinations.
- There is a time lag between organizational change, such as a merger or acquisition, and the ability to operationalize a change in quality, and sufficient time is needed after implementation before the full potential of quality improvement is achieved.
In examining how quality might be used effectively in evaluating mergers, while taking the foregoing limitations into account, we do not believe it is necessary or appropriate for the FTC to develop its own quality metrics for purposes of its oversight authority. Instead, the FTC’s oversight should be tailored to achieving the mission of the Commission using industry-accepted norms and measures.
The necessity of price and quality transparency in the health care space is clear, and both are improved for the patient when used in tandem. While there have been many important advances to achieve effective transparency, ongoing limitations necessitate caution and accuracy when evaluating quality and price transparency data to examine health care competition.
The FAH is grateful to have the opportunity to outline its recommendations to the FTC during a crucial time as health care transparency tools swiftly evolve.